All-trans retinoic acid (ATRA)-based cell differentiation therapy has been successful in treating acute promyelocytic leukemia, a unique subtype of acute myeloid leukemia (AML). However, other subtypes of AML display resistance to ATRAbased treatment. In this study, we screened natural, plantderived vibsane-type diterpenoids for their ability to induce differentiation of myeloid leukemia cells, discovering that vibsanin A potently induced differentiation of AML cell lines and primary blasts. The differentiation-inducing activity of vibsanin A was mediated through direct interaction with and activation of protein kinase C (PKC). Consistent with these findings, pharmacological blockade of PKC activity suppressed vibsanin A-induced differentiation. Mechanistically, vibsanin A-mediated activation of PKC led to induction of the ERK pathway and decreased c-Myc expression. In mouse xenograft models of AML, vibsanin A administration prolonged host survival and inhibited PKC-mediated inflammatory responses correlated with promotion of skin tumors in mice. Collectively, our results offer a preclinical proof of concept for vibsanin A as a myeloid differentiation-inducing compound, with potential application as an antileukemic agent. Cancer Res; 76(9);
Introduction
Acute myeloid leukaemia (AML), the most common type of leukemia in adults, is characterized by the proliferation of clonal precursor myeloid cells with arrested differentiation (1) . The major therapeutic approach to this disease has been the use of chemotherapeutic agents with associated life-threatening toxicity, particularly in elderly patients (2) . Although remission can be achieved in most de novo AML patients, relapse is common and long-term survival is poor for most cases. In contrast to the poor prognosis for the majority of patients with AML, the use of differentiation therapy with all-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APL), a unique subtype of AML, has introduced a paradigm for success of cell differentiation therapy for AML (3) . In APL, the application of ATRA alone or in combination with anthracycline-based chemotherapy, results in myeloid differentiation of the leukemic blasts and leads to a high rate of complete remission and the long-term survival (3, 4) . Unfortunately, ATRA is clinically effective only for the treatment of APL, and most patients usually relapse because of acquired resistance (3) .Therefore, the development of new compounds that exploit differentiation pathways is key avenues of investigation for AML patients.
Protein kinase C (PKC) is a family of phospholipid-dependent serine/threonine kinases, which are classified into three subgroups: classical (a, bI, bII, and g), novel (d, e, h, and q), and atypical (z and -i). Activation of classical enzymes (cPKC) depends on Ca 2þ and diacylglycerol (DAG), whereas novel enzymes (nPKC) are activated by diacylglycerol (DAG), and atypical enzyme (aPKC) activation takes place independently of calcium or DAG (5, 6) . The PKC family of isoenzymes is involved in key cellular processes including cell proliferation, apoptosis, and differentiation (6) . There is emerging evidence that activation of PKC plays vital functional roles in the differentiation of hematopoietic cells (7) . In particular, a number of PKC activators have been investigated for their ability to induce differentiation of myeloid leukemia cells with potent antileukemic activity. Phorbol esters are originally the most promising candidates due to their potency (8, 9) , but the potent tumor-promoting activity raises concerns about their therapeutic use. Fortunately, naturally occurring bryostatin 1, prostratin, and ingenol-3-angelate are fascinating PKC activators without tumor-promoting activities. Hence, bryostatin 1, a macrolide lactone and a nonselective activator of PKC isozymes, has been examined in clinical trials after showing promising results in cancer xenograft models (10) . However, bryostatin 1 shows minimal activity against a few special types of hematological malignancies when it was tested in clinical studies (11) (12) (13) , and the differentiation-inducing activity of bryostatin 1 upon myeloid leukemia cells still remains inconclusive (14) . Recently, the novel PKC-activating agent ingenol-3-angelate has been approved for the topical treatment of actinic keratosis, a premalignant lesion that can progress to invasive squamous cell carcinoma (15) . Meanwhile, it has been shown to induce apoptosis and differentiation in a range of myeloid leukemia cell lines and in primary AML blasts (16, 17) . Similarly, prostratin, an nontumor promoting phorbol ester, has been shown to induce differentiation of myeloid leukemia cells in vitro (18, 19) , but its therapeutic potential as an anti-HIV drug has been attracting much more attention (18, 20) . Therefore, the potential of differentiation therapy with PKC activators in AML has yet to be realized, and novel agents that specifically target PKC with differentiation-inducing activity are still in need of development.
Natural products have long been recognized as an important source of therapeutically effective drugs, and their importance in the prevention and treatment of cancer is becoming increasingly evident. Plants of genus Viburnum have proven to be a rich source of vibsane-type diterpenes with piscicidal, plant growth regulatory, and cytotoxic activities (21) (22) (23) . Vibsane-type diterpenes, however, are regarded as quite rare natural products because their occurrence has been limited to only two kinds of Viburnum plants, Viburnum awabuki and Viburnum odoratissimum and they have not been extensively studied yet (24) . In this work, we describe the identification of a novel differentiation-inducing agent, vibsanin A, an vibsane-type diterpenoid isolated from the leaves of Viburnum odoratissimum, by using HL-60 cell line-based phenotype screening. We show that vibsanin A induces differentiation of myeloid leukemia cells by targeting PKC as evidenced by the direct interaction with and activation of PKC by vibsanin A, which leads to the activation of extracellular signal-regulated protein kinases (ERK) 1 and 2 and consequently to the decreased expression of cMyc. Moreover, the antileukemic activity of vibsanin A has also been shown in murine AML xenograft models. These results indicate that vibsanin A is a powerful tool for understanding the potential pathophysiological and therapeutic roles of PKC and warrants further evaluation as potential differentiation therapy for myeloid leukemia.
Materials and Methods

Chemicals and reagents
Vibsanin A was isolated from the dried leaves of V. odoratissimum as described in Supplementary Methods. Other chemicals and reagents were all from Sigma unless stated otherwise.
Cell culture, morphology, and flow cytometry assay
The human myeloid leukemia cell lines HL-60 and U937 were obtained from China Infrastructure of Cell Line Resource (Beijing, China) and cultured under recommended conditions. The DNA profiles characteristic of cells was authenticated by STR analysis in 2015. NB4 cells (kindly gifted from Dr. Bingwei Deng, Beijing Proteome Research Center, Beijing, China) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS; HyClone) at 37 C, 5% CO 2 humidified atmosphere. Cell morphological features and cell-surface differentiation antigens were measured as described (19) . Fresh blasts from 11 cases of de novo AML patients were obtained with informed consent and study protocols were approved by the Institutional Review Board of Chinese PLA General Hospital.
RNA isolation, real-time quantitative PCR, and transcriptome analysis Total RNA was isolated by a TRizol Kit (Invitrogen). RNA was treated with DNase (Promega). Complementary DNA was synthesized according to manufacturer's instructions. Real-time quantitative PCR was performed with SYBR Green PCR Master Mixture Reagents (TOYOBO) on the CFX96 Touch TM Real-Time PCR Detection system (Bio-Rad). For the microarrays, the NimbleGen 12 Â 135K array and the dual-color analysis method were used following the manufacturer's protocol (Roche/NimbleGen). The gene expression data have been deposited in the Gene Expression Omnibus database under the accession number GSE78734.
PKC-GFP translocation assay
293-T cells were seeded onto 40-mm circular glass coverslips, and 24 hours later, were transiently transfected with GFP-tagged human PKC-a, b, g, d, h, and q subcloned into pEGFP-N1 plasmid. Translocation of PKC isoforms was visualized by confocal microscopy 48 hours after transfection.
Binding of [ 3 H]PDBu
The binding affinity of vibsanin A to purified human PKC-a, -b, -g, -d, -e, -h, and -q isoforms and PKD1 (GenWay Biotech) was determined by competition of [ 3 H]PDBu binding. [ 3 H]PDBu binding was measured as described by Lewin and Blumberg (25) .
Kinase assay
The kinase activity of PKC isoforms was assayed using histone III-S as the substrate. PKCs 
Cellular fractionation
Cells were washed twice in PBS, and then lysed by homogenization in hypotonic lysis buffer in the absence of detergent. Cell debris or nuclear fraction was removed by centrifugation at 1,000 Â g for 10 minutes at 4 C. Centrifugation at 100,000 Â g for 60 minutes at 4 C was used to isolate the cytosol (supernatant) and cell membrane (pellet) fractions.
Western blot analysis
At the end of the desired treatment, total cell lysates preparation and Western blot analysis were performed according to the procedure described before (19) .
In vivo xenograft study
Leukemic cells isolated from spleens from leukemic Mll-AF9 transgenic mice (The Jackson Laboratory) were intravenously injected into 6-to 8-week-old male C57BL/6 mice (2.5 Â 10 6 leukemic cells per mouse) 6 hours after sublethal irradiation (totally 4.5 Gy). For HL-60 xenografts, 4-to 6-week-old male NOD/SCID mice were intravenously injected HL-60 cells stably expressing the firefly luciferase (1 Â 10 6 cells per mouse) 6 hours after sublethal irradiation (totally 2.0 Gy). Three days after leukemic cell transplantation, the mice were orally treated with vehicle or vibsanin A. No animals were excluded from analysis and animal groups were not blinded. Animal handling was approved by the Animal Care and Use Committee of Animal Center in Academy of Military Medical Science (Beijing, China).
Statistical analysis
To assess correlation of the transcription profiles of vibsanin A, PMA, and ATRA in HL-60 cells, scatter plots were used and linear relationships were measured. The correlation coefficient, R 2 , that indicates the variability of intensity values in one group versus the other, was calculated using Excel software. KaplanMeier survival analysis (SPSS 10.0; SPSS Inc.) was used to compare the survival probabilities of different groups. An unpaired Student t test was used to evaluate the difference between two different treatments. P < 0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS software.
Results
Vibsanin A triggers differentiation of myeloid leukemia cells
To identify novel differentiation-inducing agents, a series of vibsane-type diterpenoids were isolated from the leaves of V. odoratissimum ( Supplementary Fig. S1A ), and screened for their ability to trigger the differentiation of HL-60 cells by detecting the expression level of CD11b, a differentiation marker of myeloid cells. Among them, a novel vibsane-type diterpenoid, designated vibsanin A (Fig. 1A) , was shown to possess the highest differentiation-inducing activity ( Supplementary  Fig. S1B ). The results showed that vibsanin A treatment increased the percentages of CD11b þ and CD14 þ cells in a concentration-dependent manner (Fig. 1B) . Vibsanin A-treated HL-60 cells in suspension became adherent to the culture plate and showed substantial changes in morphology, indicative of monocytic differentiation, as evidenced by increased cell size, lower nuclear to cytoplasmic ratio, and highly vacuolated cytoplasm ( S2A ) and upregulated the expression of CD41 and CD61 megakaryocyte cell surface markers ( Supplementary Fig. S2D ). Finally, induction of myeloid differentiation by vibsanin A in these cells was associated with an inhibition of cell growth and induction of G 1 cell-cycle arrest ( Supplementary Fig. S3 ). Next, we determined the potential differentiation-inducing effects of vibsanin A on primary blast cells from 11 cases of AML patients, according to the percentage of CD11b þ cells.
Vibsanin A induced evidence of differentiation in 10 of 11 evaluable AML patient samples, with eight samples responded at doses less than 3 mmol/L (Table 1) . We noted that one sample from a patient with M3-AML (patient 1) showed vibsanin A-mediated cell death instead of differentiation, and two samples (patient 5 and 10) exhibited low sensitivity to vibsanin A.
Vibsanin A-induced cell differentiation is dependent on the activation of PKC We next investigated the effects of other known differentiation-inducing agents, including PMA and ATRA, on the myeloid leukemia cells. Thus, a comparison of the differentiationinducing activities of vibsanin A with PMA afforded a similar phenotype in the myeloid leukemia cell differentiation assay ( . By comparing the pattern of genes induced by PMA and by vibsanin A in a nonsupervised transcriptome analysis, we also found a high similarity between the differentially expressed genes. As early as 6 hours, 89.2% of the genes affected by vibsanin A were coregulated by PMA, and the gene expression pattern was similarly evident following 24 hours of treatment (88.6%; Fig. 2A and Supplementary Fig. S4 ). In contrast, only less than 10% of the genes affected by vibsanin A were modulated by ATRA ( Fig. 2A and Supplementary Fig. S4 ). As a potential differentiating agent, PMA is also a PKC activator and has been demonstrated to induce PKC-dependent differentiation of myeloid leukemia cells (27, 28) . Thus, we next investigated whether vibsanin A-activated PKC and induced PKCmediated differentiation. We first studied the functional effects of vibsanin A on PKC activation by using PKC-GFP fusion protein translocation assay. As shown in Fig. 2C , with vibsanin A treatment, classical PKC isoforms including PKC-a, -b, and -g were translocated almost instantaneously to the plasma membrane, just as it can be seen in PMA-treated cells. Notably, vibsanin A was found to induce a pronounced translocation of novel PKC isoforms including PKC-d, -h, and -q simultaneously to the plasma membrane and to the nuclear membrane. However, unlike vibsanin A, PMA caused only the translocation of these isoforms to the plasma membrane. We also observed that treatment with vibsanin A caused a rapid shift of various classical and novel PKCs from the cytosol fraction to membrane fraction in HL-60 cells (Fig. 2D ). In contrast, vibsanin A and PMA both showed no effect on the atypical PKC-z. Prolonged treatment with PKC activators such as phorbol esters and other natural products is known to result in downregulation of different PKC isoforms (29) . In leukemia cells, PMA was able to cause downregulation of the tested classical and novel PKCs except PKC-e in K562 cells ( Supplementary Fig. S5 ). Vibsanin A, however, only downregulated PKC-bII in HL-60 cells and PKC-q in K562 cells, which showed selective activity in downregulation of PKC isoforms compared with PMA ( Supplementary Fig. S5 ).
To determine the functional role of PKC in vibsanin Ainduced AML cell differentiation, we treated HL-60 cells with GF109203X (GFX) and G€ o6983, which are blockers of both cPKCs and nPKCs (30) . Notably, pretreatment with them completely blocked vibsanin A-mediated cellular differentiation ( Fig. 2E and F) , indicating that PKC activation is essential for vibsanin A-induced differentiation of AML cells. However, pretreatment with the cPKCs inhibitor G€ o6976 (30) and nPKCs inhibitor 5-(3,4-Dimethoxyphenyl)-4-(1H-indol-5-ylamino)-3-pyridinecarbonitrile (31) had no effect ( Fig. 2E and F) . Finally, PMA showed a similar response to PKC inhibitors as vibsanin A (Supplementary Fig. S6 ).
Vibsanin A directly interacts with PKC
The identification that the close similarities between vibsanin A and PMA and the activation of PKC involved in the vibsanin A-mediated cell differentiation raised a possibility that vibsanin A might directly interact with PKC. (Fig. 3A) . Similarly, novel PKC isoforms (nPKCs: PKC-d, -e, -h, -q) showed affinity for vibsanin A in the same order although to a lesser extent than cPKC. In the case of PKD1, the K i value for vibsanin A was 15.82 AE 0.12 nmol/L, much higher than that of PKC isoforms (Fig. 3A) .
To gain finer details of the possible binding mode of vibsanin A with the PKC isoforms, we performed molecular docking experiments. It was shown that the PKC-a, -b, and -e formed hydrophilic pocket whereas the PKC-d formed hydrophobic pocket to interact with vibsanin A (Fig. 3B-E and Supplementary Fig. S8 ). Compared with the binding energy between PKC and vibsanin A, the complex PKC-e and vibsanin A was the most stable whereas the PKC-d and vibsanin A was the most unstable (Fig. 3F) . For the PKC-a, -b, and -d, vibsanin A inserted the pocket with the aliphatic side chain, and the ring chain was exposed to the solvent. Although vibsanin A interacted with PKC-e, the whole molecule interacted with the protein. The ring and aliphatic were all involved in the binding.
We next tested whether vibsanin A increased PKC activity in an in vitro kinase assay. The results demonstrated that vibsanin A increased the basal activity of both cPKC and nPKC in a dose-dependent manner with similar potency indicated by EC 50 s (Fig. 3G and H) . However, vibsanin A did not activate PKD1 in such conditions although it was able to bind PKD1 in vitro.
Downregulation of c-Myc expression mediates vibsanin A-induced differentiation
The oncogene c-Myc blocks myeloid differentiation, and its downregulation is critical for myeloid cell differentiation (32) . Upon vibsanin A treatment, HL-60 cells showed a strong concentration-dependent loss of protein levels of c-Myc, which was accompanied by an elevation in expression of C/EBPb and p21 (Fig. 4A) , which are transcriptional suppressed by c-Myc and are pivotal for normal myeloid differentiation (33, 34) . The reduction of c-Myc expression by vibsanin A could be regulated at the transcriptional level or at the posttranscriptional level. It was shown that the downregulation of c-Myc protein was detectable within 1 hour of treatment and highly significant from 3 hours of treatment with corresponding decrease in c-Myc mRNA levels ( Fig. 4B and C) . Previous reports have shown that c-Myc is a very unstable protein with half-life between 20 and 30 minutes and its rapid turnover can be mediated by the ubiquitin-dependent proteasome pathway (35) . Thus, we examined whether vibsanin A affects c-Myc protein degradation. As shown in Fig. 4D , vibsanin A was shown to markedly promote the degradation of c-Myc and shorten its half-life by using a cycloheximide chase assay. Moreover, treatment with proteasome inhibitor MG132 blocked the c-Myc suppression and cellular differentiation induced by vibsanin A (Fig. 4E and F) , suggesting the involvement of proteasomedependent degradation of c-Myc in the vibsanin A-mediated myeloid differentiation. To further evaluate whether suppression of c-Myc confers the differentiation-inducing effects of vibsanin A, we generated HL-60 cells in which the c-Myc cDNA was ectopically expressed, which resulted in the mRNA but not the protein levels of c-Myc that were dramatically elevated but both significantly resistant to vibsanin A-induced suppression ( Fig. 4G and H) . Ectopic c-Myc expression conferred complete resistance to myeloid differentiation and G 1 cell-cycle arrest induced by vibsanin A (Fig. 4I and Supplementary Fig. S9 ). Consistently, induction of c-Myc antagonized the upregulation of C/EBPb and p21 at both mRNA and protein levels by vibsanin A (Fig. 4G and H) . We next sought to confirm the functional role of c-Myc in the vibsanin A-mediated cellular differentiation using another AML cell line NB4 with relative low endogenous expression of c-Myc (Supplementary Fig. S10 ). As expected, infected NB4 cells showed increased expression of the c-Myc protein, which led to the inhibition of downregulation of c-Myc with slight decrease of upregulation of C/EBPb and p21 and consequently to the cell differentiation induced by vibsanin A (Supplementary Fig. S10 ). These results, collectively, support an important role for downregulation of c-Myc in vibsanin A-induced differentiation of AML cells.
Vibsanin A-induced c-Myc downregulation is mediated by the PKC/ERK signaling pathway
Next, we addressed how vibsanin A-mediated PKC activation decreased c-Myc expression. It has been well documented that MAPKs, especially MEK/ERK/MAP kinase signaling pathway, play an important role in myeloid differentiation (36, 37) . In line with these reports, vibsanin A induced the phosphorylation of Raf-1, MEK, and ERK in a dose-dependent manner, with marked increases in p38 and JNK phosphorylation (Fig. 5A) . However, only inhibitor of ERK, but not of JNK and p38, abrogated vibsanin A-induced cellular differentiation (Fig. 5B and C) . Pretreatment with the ERK inhibitor U0126 blocked ERK phosphorylation and antagonized vibsanin A-induced upregulation of C/EBPb and p21 (Fig. 5D) . Importantly, inhibition of ERK activation with U0126 effectively reversed the vibsanin A-induced suppression of c-Myc expression levels (Fig. 5E ), which might be mediated by inhibition of the dephosphorylation of Ser62 by vibsanin A because Ser62 phosphorylation at c-Myc has been shown to be crucial for its protein stability (38) . Moreover, pretreatment with GFX blocked vibsanin A-induced Raf-1, MEK, and ERK activation and effectively antagonized upregulation of C/EBPb and p21 protein levels and downregulation of c-Myc protein levels ( Fig.  5D and E) . These results indicate that reduction of c-Myc expression by vibsanin A is at least in part a downstream effect of PKCactivated ERK proteins.
Vibsanin A prolongs survival of mouse xenograft models of AML
To investigate the in vivo effects of vibsanin A, we intravenously transplanted leukemic blasts from Mll-AF9 transgenic mice into sublethally irradiated C57BL/6 recipients to generate AML mice. All of these mice rapidly developed an AML phenotype with anemia, high white blood cell (WBC) count, and hepatosplenomegaly (Supplementary Table S1 ). In mice treated with vibsanin A, the level of WBC count increase was depressed. Moreover, mice treated with vibsanin A clearly had a survival benefit over vehicle-treated mice (Fig. 6A ). To confirm the in vivo efficacy of vibsanin A, we further intravenously transplanted HL-60 cells stably expressing the firefly luciferase (Fig. 6B) . Median overall survival of vibsanin Atreated animals was significantly longer than control animals (Fig. 6C) . Finally, vibsanin A administration was well tolerated, and no significant weight loss was observed (Supplementary Fig.   S11 ). Together, these results demonstrate that vibsanin A has antitumor efficacy in mouse xenograft models of AML leukemia.
Vibsanin A inhibits PMA-induced inflammatory responses in mouse skin
PMA is the most widely studied tumor promoter and exerts tumor promoting, inflammatory, and hyperplastic activity in mouse skin (6, 39) . We next compared the hyperplastic effects of vibsanin A and PMA in mouse skin model. A dose of 7.5 nmol PMA induced strong hyperplasia on the back skin of CD-1 mice, whereas even the highest test concentration (2.5 mmol) of vibsanin A did not cause significant epidermal hyperplasia at various time posttreatment (Supplementary Fig. S12 ). Furthermore, the topical application of vibsanin A, prior to that of PMA application to mouse skin resulted in inhibition in the induction of epidermal hyperplasia in a dose-dependent manner (Fig. 6D) . Consistently, vibsanin A significantly reduce the level of skin edema induced by PMA ( Supplementary Fig. S12 ). Together, these results revealed an evident inhibitory effect of vibsanin A on PMA-mediated inflammatory responses.
Discussion
In this study, we provided the first demonstration that vibsanin A, a vibsane-type diterpene, exhibited potent differentiationinducing activity in myeloid cell lines and primary patientderived blasts with antileukemic effect on mouse xenograft models. Importantly, we identified vibsanin A as a potent and competitive activator of PKC in biochemical, structural, and cellular analysis and established a key role for PKC signaling in vibsanin A-induced myeloid differentiation.
The principal molecular mechanism drawn from the experiments reported here links the signaling pathways activated by vibsanin A and by PMA. A comparison of the differentiationinducing activities of vibsanin A with PMA afforded a very similar phenotype in cellular differentiation assay and gene expression analysis. Vibsanin A activated PKC with inducing cellular translocation of various PKCs to the plasma membrane and/or the nuclear membrane, which is one hallmark of PKC activation (40) . Conversely, pharmacological inhibition of PKC blocked vibsanin A-induced cellular differentiation, suggesting a predominant role of PKC in the differentiation. Prolonged activation of PKCs with phorbol esters may cause their downregulation, and different PKC ligands may drive different patterns of PKC localization and downregulation. For example, bryostatin 1 translocated PKC-d predominantly to the nuclear membrane and inversely prevented PKC-d translocation to the plasma membrane and its downregulation by PMA (29, 41) . We found that vibsanin A showed selectivity to a degree in downregulation of the PKC isozymes as compared with PMA. Vibsanin A also caused simultaneous translocation of nPKCs to the plasma membrane and the nuclear membrane, whereas PMA induces only translocation to the plasma membrane in PKC-GFP translocation assay. The distribution of PKC isoforms in different cellular compartments determines the functions of these isoforms by presenting them to different substrates and interaction partners. Therefore, different patterns of localization and/or downregulation of PKC isoforms could contribute to the differing biological response of vibsanin A compared with the other PKC ligands, such as we indeed observed for inflammatory responses.
Classical PKC ligands such as phorbol esters, Ingenol 3-angelate, and prostratin serve as structural mimetics of DAG and bind to the C1 domains of PKC. In this paper, the competitive inhibition of PKC by vibsanin A with respect to ligands for the phorbol ester binding site, and the ability of vibsanin A to compete with [ 3 H]PDBu for binding, raised a possibility that vibsanin A interacts specifically with the phorbol binding C1-domain. In line with this assumption, molecular docking studies revealed that vibsanin A interacted with the C1 domains of PKC. A highly favorable pattern of hydrophilic or hydrophobic interactions with the expected entropy gain due to conformational restriction appears to contribute to its high binding affinity. The observation that the binding energy obtained from the models do not always corroborate with the experimental binding data indicate the fact that both the proteins and ligands can undergo conformational changes in solutions. Although the detailed structural determinants for vibsanin A binding to PKCs remains to be investigated, our results definitely identify vibsanin A as a potent PKC activator. Furthermore, as an 11-membered ring compound, vibsanin A bears significant structural differences relative to other PKC activators including phorbol esters, bryostatins, ingenols, and colleagues. Most of these known PKC activators are highly complex in their chemical structure, which makes a great obstacle in structural modification. Obviously, vibsanin A shows a less constrained structure than them, and the first total synthesis of vibsanin A has been achieved (42) . Thus, structural optimization to screen and improve the activity of such vibsane-type compounds is practicable. c-Myc is an oncogenic transcription factor, and it is found deregulated in about half of human tumors and appears frequently associated with tumor progression in solid tumors and leukemia (43, 44) . One of the most relevant activities of c-Myc in carcinogenesis is the impairment of cell differentiation (45) , and repression of c-myc is required for terminal differentiation of many cell types, including myeloid cells (46, 47) . Recently, we have presented an essential role for c-Myc suppression in the differentiation-inducing effects of prostratin as a PKC activator (19) . In light of these observations, it was intriguing that c-Myc was rapidly downregulated at transcriptional and posttranscriptional levels by vibsanin A treatment, and the fact that block of the degradation of endogenous c-Myc and the enforced ectopic expression of c-Myc both effectively antagonized vibsanin Amediated differentiation strongly supported the role of decreased c-Myc in vibsanin A-induced AML cell differentiation. Our further investigations showed that repression of c-Myc was mediated by PKC-dependent activation of ERK/MAP kinase signaling pathway, which has been widely shown to mediate terminal differentiation in various lineages of hematopoietic cells (36, 37) . We conclude that vibsanin A induces AML cell differentiation by activating PKC, followed by ERK activation, which leads to c-Myc downregulation.
PKCs have been shown to play a complex role in tumorigenesis, which is initially recognized from the tumor-promoting activity of phorbol esters in mouse skin (6) . As potent PKC activators, phorbol esters evoke diverse and dramatic effects on mouse skin, including tumor promotion, inflammation, and hyperplasia (39) . However, prostratin, a nontumor-promoting phorbol ester, has been shown to inhibit above effects induced by PMA with identified antipromoting activity (48) . Similarly, vibsanin A was shown to have no inflammatory activity with an evident inhibitory effect on PMA-mediated inflammatory responses. Induction of hyperplasia and its maintenance upon repeated treatment have proved so far to correlate best with tumor promoting activity in the mouse skin model system (49) . In light of this, our findings therefor supported the preliminary conclusion that vibsanin A is not tumor promoting but antipromoting. Indeed, Antal and colleagues have recently established that PKC isozymes generally function as tumor suppressors, indicating that therapies should focus on restoring, not inhibiting, PKC activity (50) . In this context, classic PKC agonists such as PMA, which showed tumor-promoting effects, and bryostatin-1, which failed as a therapeutic, all downregulate PKC and likely result in the inhibition of PKC activity. Conversely, vibsanin A activated PKC with less downregulation of them in leukemia cells, suggesting a promising clinical potential (50) . Overall, the potent antileukemic activity and the absence of inflammatory activity with predicted antipromoting potential with vibsanin A is encouraging. These particularities highlight vibsanin A and related vibsanin diterpenes as a family of natural products worthy of further investigation in the efforts toward safe and efficient differentiation therapy of AML.
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